Market Signal Briefing

, /PRNewswire/ -- TriNet (NYSE: TNET), a leading provider of comprehensive human resources solutions for small and medium-size businesses (SMBs), today announced the results of a new survey conducted with Harvard Business Review Analytic Services. Among 230 survey respondents familiar with their SMB's U.S. talent practices, 'The New Talent Playbook for Small and Midsize Businesses in the Age of AI' reveals that 76% expect their organization to increase its use of AI in the next 12 months, highlighting the technology's growing presence in everyday operations. However, just 19% of respondents feel their organization is highly prepared to recruit or develop the AI skills needed, underscoring a widening capability gap."

Harvard Business Review Analytic Services Survey, Sponsored by TriNet, Finds SMBs Accelerating AI Adoption and Embracing New Opportunities for Workforce Skill Development "AI is fundamentally transforming the way SMBs operate," said Catherine Wragg, Chief People Officer at TriNet. "At TriNet, our commitment to putting SMB customers at the center of everything we do drives us to understand their evolving needs. This research underscores that while SMBs are moving swiftly to embrace AI, many are still navigating the best ways to equip their people for this new era." She continued, "Embracing AI presents an opportunity to not only adopt new technology, but also to reimagine workforce strategies, planning, and skill development, empowering SMBs to accelerate AI adoption and unlock exciting new avenues for workforce growth and success."

Key Survey Findings

56% of those surveyed expect AI will require their SMB to develop or train employees differently. 49% anticipate changes in existing roles and responsibilities due to AI. 56% expect difficulty determining which AI skills their organization actually needs. Looking ahead, 55% say one of the most in demand AI-related skills will be experience using AI tools to accomplish work tasks. 70% report AI is driving the need to find talent with human capabilities such as creativity, intuition, and discernment to work with AI. SMBs are already feeling pressure to expand internal AI capabilities. Nearly half of respondents (49%) anticipate difficulty training/upskilling existing employees on AI, while 37% expect challenges evaluating candidates' AI skills and experience. Despite these challenges, SMBs remain committed to future ready talent development: 79% of respondents agree that AI is driving the need to upskill existing talent.

The report also highlights emerging emphasis on human-centered skills that AI cannot replicate, resulting in a growing focus on human-AI collaboration. Many SMBs prioritize industry experience, emotional intelligence, and judgment foundational qualities required to ensure AI is deployed ethically and effectively.

Download the full Harvard Business Review Analytic Services survey here.

About TriNet
TriNet is a leading provider of Human Resources solutions for small and medium-size businesses, offering advanced technology-enabled services that include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. Our long-term objective is to be the premier provider of HR services for a broad range of SMBs through industry leading benefits, sales distribution excellence, and a world class services delivery model. For more information, visit TriNet.com or follow us on Facebook, LinkedIn and Instagram.

SOURCE TriNet

Editas Medicine (EDIT - Free Report) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +77.78%. A quarter ago, it was expected that this genome editing company would post a loss of $0.38 per share when it actually produced a loss of $0.28, delivering a surprise of +26.32%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Editas, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.74 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 280.05%. This compares to year-ago revenues of $30.6 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Editas shares have lost about 2.4% since the beginning of the year versus the S&P 500's decline of 1.5%.

What's Next for Editas?While Editas has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Editas was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $2.4 million in revenues for the coming quarter and -$1.13 on $22.04 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

MeiraGTx Holdings PLC (MGTX - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025.

This company is expected to post quarterly loss of $0.60 per share in its upcoming report, which represents a year-over-year change of -20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

MeiraGTx Holdings PLC's revenues are expected to be $2.41 million, down 88.7% from the year-ago quarter.

An updated edition of the January 15, 2026 article.

Nuclear energy is increasingly being recognized as a critical solution to meet the world’s rising demand for clean electricity. As utilities continue transitioning toward low-carbon power sources, nuclear plants stand out for their ability to deliver dependable, carbon-free generation. Unlike solar and wind power, which are weather-dependent, nuclear energy provides consistent, around-the-clock output.

The renewed momentum in the sector is reflected in the extension of operating licenses for existing reactors, ongoing development of Small Modular Reactors (SMRs), approvals for the construction of new nuclear facilities, and the restart of previously shut U.S. reactors. Investments from major technology companies to support SMR development further underscore the growing investor interest in nuclear energy stocks.

In the United States, new policies aim to expand nuclear capacity from roughly 100 gigawatts (“GW”) in 2024 to about 400 GW by 2050. The nuclear energy sector is gaining momentum as it supports global decarbonization goals.

Favorable regulations and ongoing R&D in advanced SMRs are strengthening its outlook. Meanwhile, rising demand for reliable 24/7 clean power from AI data centers, manufacturing reshoring and electric vehicles is creating new growth opportunities. Government initiatives to boost domestic uranium supply are further supporting the sector’s momentum.

With this increasing importance, nuclear energy-related stocks, such as Entergy Corporation (ETR - Free Report) , Nano Nuclear Energy Inc. (NNE - Free Report) and NexGen Energy (NXE - Free Report) , are becoming attractive investment options. Unlike other clean energy sources affected by intermittency, nuclear power plants provide a consistent and stable energy output, operating around the clock except during planned maintenance intervals.

Compared with other clean energy sources, nuclear power requires significantly less land to generate the same amount of clean electricity. Additionally, while all traditional energy sources produce waste, nuclear energy stands apart for its highly regulated, secure and systematic approach to waste management and storage. Increasing adoption of electric vehicles, rising demand from the power grids and the development of large artificial intelligence-powered data centers are increasing the importance of nuclear power plants.

Nuclear Energy stocks have huge potential and can offer significant growth opportunities for investors. Our Nuclear Energy Screen makes it easier for investors to locate high-potential stocks at any given time. Apart from the stocks mentioned above, investors can also explore stocks like Denison Mines Corp. (DNN - Free Report) and BHP Group Limited (BHP - Free Report) , as these companies ensure the supply of uranium for the smooth running of nuclear power plants.

Ready to uncover more transformative thematic investment ideas? Explore 36 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.

Entergy Corporation’s nuclear energy portfolio supports its long-term growth strategy and transition to cleaner energy. As of Dec. 31. 2025, the company’s major nuclear plants generated around 21% of its total power capacity. Entergy is actively pursuing license extensions and system upgrades at these facilities, targeting an additional 275 MW through uprates. These enhancements not only increase generation but also highlight Entergy’s ongoing commitment to delivering stable, carbon-free baseload electricity. The company has taken initiatives to add 40 MW at its River Bend nuclear plant in Louisiana.

Entergy is advancing efforts to explore next-generation nuclear technologies to further lower emissions. The company has secured a permit in Mississippi for a potential new reactor site and is working to engage industrial customers and technology firms, particularly those in the AI and data sectors. These partnerships aim to collaboratively address the financial and regulatory challenges associated with developing next-generation nuclear projects.

Entergy’s nuclear expansion is gaining momentum as electricity demand rises from AI-driven industries and large data centers. Supported by strong market demand and a forward-looking strategy, the company’s nuclear initiatives are well-positioned to enhance regional energy reliability and advance broader U.S. decarbonization goals.

This Zacks Rank #2 (Buy) company intends to invest $43 billion during the 2026-2029 period to fund the company's generation fleet transition and grid modernization, and expand its zero-carbon generation portfolio.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Nano Nuclear Energy Inc. is a microreactor developer, aiming to become the leading advanced nuclear microreactor developer in North America. The company is advancing KRONOS toward licensing and already has a pipeline of potential commercial customers and strategic partners in the United States and globally for its KRONOS MMRTM system.

Uranium plays a vital role in the successful operation of nuclear power plants. The company continues to address the key bottlenecks within the nuclear fuel supply chain and is in discussion with different providers for securing a dependable uranium source for NANO Nuclear Energy’s future fuel requirements.

Nano Nuclear Energy has completed the assembly of its proprietary Annular Linear Induction Pump technology prototype and expects to begin commercial sales efforts. The milestone demonstrates the company’s ability to advance its technology from initial design through construction and successful demonstration.

This Zacks Rank #2 company has a growing pipeline of opportunities with potential AI data center, industrial and military-related customers for its KRONOS MM system.

NexGen Energy is emerging as an important player in the global nuclear fuel supply chain, led by its flagship Rook I uranium project in Canada’s Athabasca Basin. As nuclear power gains renewed importance in the global energy transition, the company is well-positioned to benefit from rising uranium demand. Government support for nuclear generation to meet decarbonization goals and rising electricity consumption creates a favorable environment for uranium developers like NexGen Energy.

NexGen Energy reached a key milestone in 2026 after securing final approval from the Canadian Nuclear Safety Commission to begin site preparation and construction of the Rook I project. Once operational around 2030, the project could produce up to 30 million pounds of uranium annually and will be ready to meet the demand from nuclear power plants.

Zacks #2 Ranked NexGen Energy’s long-term outlook remains favorable as global interest in nuclear power rises and uranium supply tightens. Increasing electricity demand from AI technologies and large data centers is expected to boost nuclear expansion and uranium consumption. Backed by a high-quality resource base and a clear path to production, the company is well-positioned to become a leading uranium supplier and generate long-term investor value.

BROSSARD, Quebec, March 09, 2026 (GLOBE NEWSWIRE) -- Please note that the version of the release issued earlier today by G Mining Ventures Corp. (TSX:GMIN, OTCQX:GMINF) was incorrect. The correct version of the release follows: 

G Mining Ventures Corp. (“GMIN” or the “Corporation”) (TSX:GMIN, OTCQX:GMINF) announces that the Corporation’s largest shareholder, La Mancha Investments S.à r.l. (“La Mancha”), has elected to exercise its top-up right pursuant to the investor rights agreement between the Corporation and La Mancha that was initially entered into on July 22, 2022 and subsequently updated on July 15, 2024, which allows La Mancha to increase its ownership to up to 19.9%. This transaction represented the final opportunity for La Mancha to exercise its right to increase its ownership to such level, after which La Mancha retains only customary anti-dilution rights.

Louis-Pierre Gignac, President and Chief Executive Officer, stated: “This additional investment by La Mancha further demonstrates its long-term support and its strong conviction in our ability to create shareholder value as we continue our evolution into a leading intermediate gold producer.”

In connection with the exercise of La Mancha’s long-standing top-up right, the Corporation has agreed to issue 9,311,745 common shares (the “Top-Up Shares”) to La Mancha at a price of CAD45.89 per Top-Up Share, for aggregate gross proceeds of approximately CAD427 million. There are no fees or commissions payable on the La Mancha subscription, which is expected to close on or about March 11, 2026, subject to customary closing conditions, including receipt of the Toronto Stock Exchange approval. Following the issuance of the Top-Up Shares, La Mancha will beneficially own approximately 19.9% of the issued and outstanding common shares of the Corporation.

Vincent Benoit, Managing Partner and Chief Investment Officer of La Mancha, commented: “The investment reflects that La Mancha continues to see significant value creation potential in the Corporation. G Mining’s strong performance and execution to date have reinforced La Mancha’s original investment thesis, which remains firmly supported by the Corporation’s growth strategy, portfolio of high-quality gold assets in Latin America, and highly experienced management team with a proven track record of building and operating mines.”

The Oko West Gold Project remains on-budget and on-schedule for first gold pour in the second half of 2027 and continues to be fully funded by the Corporation’s balance sheet and cash flow. The Corporation intends to use the proceeds from the issuance of the Top-Up Shares to reduce reliance on debt pertaining to Oko West Project development, increase exploration efforts, accelerate debt repayment, and for general corporate purposes.

Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions

La Mancha is a related party to the Corporation and as such, the issuance of the Top-Up Shares to La Mancha constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Corporation is relying on exemptions from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a) in respect of such issuance as the fair market value of the transaction does not exceed 25% of the Corporation's market capitalization.

About G Mining Ventures Corp.
G Mining Ventures Corp. is a mining company engaged in the development, operation and exploration of precious metal projects to capitalize on the value uplift from successful mine development. GMIN is well-positioned to grow into the next mid-tier precious metals producer by leveraging strong access to capital and proven development expertise. GMIN is currently anchored in mining-friendly jurisdictions: Brazil, with the Tocantinzinho Gold Mine and the Gurupi Project as well as Guyana, with the Oko West Project. GMIN trades on the TSX under the symbol “GMIN”.

Additional Information 
For further information on GMIN, please visit the website at www.gmin.gold or contact:  

Jean-François Lemonde 
Vice President, Investor Relations 
514.299.4926
[email protected]

Cautionary Statement on Forward-Looking Information
All statements, other than statements of historical fact, contained in this press release constitute “forward-looking information” and “forward-looking statements” within the meaning of certain securities laws and are based on expectations and projections as of the date of this press release. Beforehand, it must be noted that this press release’s subject matter is forward-looking in its essence and nature. Forward-looking statements contained in this press release include, without limitation, those related to (i) the acceptance of the Subscription by the Toronto Stock Exchange; (ii) the satisfaction of the closing conditions relating to the Subscription; (iii) the timing relating to the closing of the Subscription; (iv) the use of proceeds relating to the Subscription; (v) the Corporation’s ability to create shareholder value and to continue its evolution into a leading intermediate gold producer; (vi) the budget and schedule of the Oko West Gold Project and, as usual, the section entitled “About G Mining Ventures Corp.”, as well as the quoted comments of GMIN’s President and Chief Executive Officer.

Forward-looking statements are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Such assumptions include, without limitation, those relating to the successful closing of the Subscription, the budget and schedule of the Oko West Gold Project and those underlying the items listed in the above section entitled “About G Mining Ventures Corp.”.

Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that, notably but without limitation, the Subscription will close successfully, as future events could differ materially from what is currently anticipated by the Corporation.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in the Corporation’s other filings with the securities regulators of Canada including, but not limited to, the cautionary statements made in the relevant sections of the Corporation’s (i) Annual Information Form dated March 27, 2025, for the financial year ended December 31, 2024, and (ii) Management Discussion & Analysis. The Corporation cautions that the foregoing list of factors that may affect future results is not exhaustive, and new, unforeseeable risks may arise from time to time. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway

RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease.

Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. In addition, the antibody assay companion diagnostic, which is designed to screen patients for eligibility with isaralgagene civaparvovec, has been submitted to, and accepted by, the FDA’s Center for Devices and Radiological Health (CDRH) seeking Premarket Approval (PMA).

Sangamo believes that the totality of data from the registrational STAAR study demonstrates the potential of isaralgagene civaparvovec as a one-time, well-tolerated and durable gene therapy treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift the Fabry treatment paradigm. Furthermore, the STAAR study demonstrated a positive mean annualized eGFR slope at 52-weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. These data were presented via four platform presentations and in poster presentations at the recent 22nd Annual WORLDSymposium™. These data are available on Sangamo’s website on the Presentations page.

About the STAAR Study
The Phase 1/2 STAAR study is a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec, or ST-920, a gene therapy product candidate in patients with Fabry disease. Isaralgagene civaparvovec requires a one-time infusion without preconditioning. Isaralgagene civaparvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency.

About Fabry Disease
Fabry disease is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA), which leads to deficient alpha-galactosidase A (α-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in the cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin. Symptoms of Fabry disease can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm; the potential for isaralgagene civaparvovec to qualify for and receive approval under the FDA’s accelerated approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval; expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civaparvovec; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo’s lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a commercialization partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that preliminary or topline data is not indicative of final results, that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, including that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; Sangamo’s need for substantial additional funding to execute its operating plan and to continue to operate as a going concern; the effects of macroeconomic factors or financial challenges on the global business environment, healthcare systems and Sangamo’s business and operations; the research and development process; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the potential for technological developments that obviate technologies used by Sangamo; Sangamo’s reliance on collaborators and the potential inability to secure additional collaborations; and Sangamo’s ability to achieve expected future financial performance.

All forward-looking statements about Sangamo’s future plans and expectations, including Sangamo’s development plans for its product candidates, are subject to Sangamo’s ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners will be able to develop commercially viable products. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo’s Securities and Exchange Commission, or SEC, filings and reports, including in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2024, as supplemented by its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each filed with the SEC, and future filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

Contacts

Investor Relations and Media Inquiries
Louise Wilkie
[email protected]
[email protected]

, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:

Eurogin HPV Conference (Vienna, Austria)
Date: Thursday, March 19
Time: 8:00 AM CET
Presentation: DNA Immunotherapy INO-3107 Demonstrates Long-Term Surgical Intervention Reduction in HPV-6 & 11 RRP

World Vaccine Congress DC (Washington, DC)
Date: Monday, March 30
Time: 11:50 AM ET
Presentation: Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVID

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, [email protected] 

SOURCE INOVIO Pharmaceuticals, Inc.

SAN JOSE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), the technology company known for developing foundational innovations that enable next-generation solutions for the semiconductor and media industries, today announced it has entered into a multi-year license agreement with Advanced Micro Devices (AMD) for access to Adeia’s comprehensive semiconductor intellectual property (IP) portfolio. The agreement also resolves all outstanding litigation between the companies.

“We are pleased to reach this agreement with AMD, a global leader in high-performance computing and advanced semiconductor solutions,” said Paul E. Davis, chief executive officer of Adeia. “Resolving our disputes allows both companies to move forward and creates an opportunity for exploring future collaborations on advanced semiconductor technologies.”

Adeia has pioneered fundamental advances in the semiconductor industry over the last 30 years. With a large and growing portfolio of intellectual property covering hybrid bonding, semiconductor packaging and semiconductor processing technologies, Adeia licenses and partners with leading semiconductor companies around the world.

About Adeia Inc.

Adeia (Nasdaq: ADEA) is the technology company known for developing foundational innovations that enable next-generation solutions for the semiconductor and media industries. We invent and license foundational technologies that shape the future of digital entertainment, electronics, and high-performance computing. Our portfolio transforms technologies into an experience that is intelligent, immersive, and personal. For more, please visit www.adeia.com.

For Information Contact:

Adeia Investor Relations
Chris Chaney
[email protected]

Adeia Media Relations
Dr. Mark Kokes
[email protected]

Marketing Agreement Establishes Powerful National Distribution Channel and Expands Marpai's Revenue Growth Opportunity

, /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (PBM) services, today announced the execution of a transformational marketing agreement dramatically expanding the national reach of its high-growth pharmacy benefit management division, providing access to a network representing up to 1.5 million covered employees for MarpaiRx.

The agreement creates a powerful new distribution channel for MarpaiRx's pharmacy benefit solutions and broader healthcare technology platform, enabling the Company to introduce its services to large employer groups, third-party administrators, and other healthcare organizations across the United States.

Through this collaboration, Marpai expects to gain access to a substantial pipeline of potential new business opportunities, significantly expanding the Company's addressable market and positioning MarpaiRx for accelerated growth.

Significant Revenue Opportunity

Management believes the scale of this distribution network represents a major strategic growth opportunity for the Company. Even modest adoption across this population of covered lives could represent a meaningful expansion of Marpai's pharmacy benefit management business.

The marketing agreement offers potential access of up to 1.5 million covered lives, representing a multiple of Marpai's current covered population and significantly expanding the Company's addressable market and long-term revenue opportunity. Within the pharmacy benefit management industry, revenue is typically generated on a per-member basis, meaning that as covered lives are added to the platform, they can contribute recurring revenue streams that scale with MarpaiRx's platform.

MarpaiRx's believes that its existing infrastructure is sufficiently robust to service the potential new members.

With the marketing agreement, Marpai expects opportunities to introduce its broader healthcare solutions across the same population, including third-party administration services, advanced healthcare analytics, and consulting capabilities.

"This agreement represents a major milestone for Marpai and a significant expansion of our potential growth runway," said Damien Lamendola, CEO of Marpai, Inc. "Gaining access to a network that could potentially reach up to 1.5 million employees dramatically expands our addressable market. Even modest penetration across this population of covered lives has the potential to create a substantial new revenue stream for MarpaiRx and accelerate the Company's overall growth trajectory."

Built for Scale

MarpaiRx provides a comprehensive suite of pharmacy benefit management services designed to reduce pharmacy costs for employers while improving member outcomes. The platform includes manufacturer rebate optimization, patient assistance programs, copay management solutions, and advanced healthcare analytics designed to help employers manage rising pharmacy costs.

The Company believes its transparent, technology-enabled PBM model positions MarpaiRx as an attractive alternative to traditional pharmacy benefit management offerings.

"Our MarpaiRx platform has been built specifically to scale across large populations of covered lives," said Mimi Davis, President of MarpaiRx. "This agreement gives us the opportunity to showcase our capabilities to a very large national audience while delivering meaningful pharmacy cost savings for employers and plan members."

Entering a New Phase of Growth

The marketing agreement significantly expands Marpai's distribution capabilities and positions the Company to pursue rapid growth within the large and expanding pharmacy benefit management market.

With scalable infrastructure already in place, Marpai believes the opportunity created by this partnership could support accelerating revenue growth and increasing operating leverage as additional covered lives are onboarded over time.

This agreement represents another important step in Marpai's strategy to rapidly expand the MarpaiRx platform and drive sustained revenue growth across the Company's healthcare technology ecosystem.

"We believe this agreement positions Marpai to enter a new phase of expansion, supported by a large and growing pipeline of potential covered lives," added Lamendola. "Our focus now is on executing against this opportunity and converting this significant market access into long-term recurring revenue and shareholder value."

About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA, PBM and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $150 billion TPA sector serving self-funded employer health plans representing over $1.5 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://ir.marpaihealth.com.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward-looking statements when it discusses the potential access of up to 1.5 million covered lives which may significantly expand its addressable market, that the agreement dramatically expands the national reach of its high-growth pharmacy benefit management division, MarpaiRx, the potential benefits that may be derived as a result of the agreement, that MarpaiRx believes that its existing infrastructure is sufficiently robust to service the potential new members, that the agreement represents a major milestone and a significant expansion for the potential of its growth runway, that the agreement has the potential to create a substantial new revenue stream and accelerate its overall growth trajectory, its belief that its transparent, technology-enabled PBM model positions MarpaiRx as an attractive alternative to traditional pharmacy benefit management offerings and the potential for converting the significant market access into long-term recurring revenue and shareholder value. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

SOURCE Marpai

ARS Pharmaceuticals, Inc. (SPRY - Free Report) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -0.96%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.52, delivering a surprise of -15.56%.

Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

ARS Pharmaceuticals, Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of $28.09 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 9.10%. This compares to year-ago revenues of $86.58 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

ARS Pharmaceuticals, Inc. shares have lost about 22.2% since the beginning of the year versus the S&P 500's decline of 1.5%.

What's Next for ARS Pharmaceuticals, Inc.?While ARS Pharmaceuticals, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for ARS Pharmaceuticals, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.44 on $25.86 million in revenues for the coming quarter and -$1.41 on $177.14 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Guardian Pharmacy Services (GRDN - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on March 11.

This provider of pharmacy services to long-term care facilities is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of +12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Guardian Pharmacy Services' revenues are expected to be $388.27 million, up 14.7% from the year-ago quarter.

The S&P 500 Index continued its strong downward trend last week, reaching its lowest level since December 17 last year. It ended the week at $6,740, down substantially from the year-to-date high of $7,000. Let's explore some of the top catalysts for the SPY, IVV, and VOO ETFs this week.

US inflation report A key catalyst for the S&P 500 and its ETFs this week will be the upcoming US consumer inflation report on Wednesday.

This is a crucial report that forms the second part of the Federal Reserve’s dual role after the labor report. 

Data released on Friday showed that the economy shed over 92,000 jobs in February, that worst reading in years. The unemployment rate jumped to 4.4%, while wage growth remained steady.

Economists expect the upcoming US inflation report to show that the headline Consumer Price Index (CPI) rose to 2.5% in February, while the core CPI remained unchanged at 2.5%.

A higher inflation report than expected will make it hard for the Federal Reserve to cut interest rates as Donald Trump has suggested. The S&P 500 Index and other indices do well when the Fed is cutting interest rates.

US and Iran war The most important catalyst for the S&P 500 Index will be the ongoing war in Iran, which escalated during the weekend, with Israel bombing a key Iranian refinery. 

This war has led to a surge in energy prices in the United States and other countries. Brent, the global benchmark, has jumped from the year-to-date low of $55 to over $100. Similarly, the US oil benchmark has continued soaring aa traffic at the Strait of Hormuz fades.

The price of other energy products like natural gas and gasoline have continued rising this year, which will lead to a higher inflation rate in the US.

While energy companies in the S&P 500 Index are benefiting, other sectors, especially transportation and manufacturing, are all under substantial pressure as the war continues

Signs that the war is ending will be bullish for the S&P 500 and other US indices. A good example of this happened on Wednesday last week when the media reported that Iran had reached out to the United States for talks to end the war.

Top corporate earnings The other key catalyst for the S&P 500, SPY, IVV, and VOO ETFs is the upcoming corporate earnings in the United States. 

While the earnings season has largely ended, some important companies will release their numbers this week.

Hewlett-Packard Enterprise and Casey’s General Stores will release their numbers on Monday. Oracle, a top player in the AI industry, will release its results on Tuesday.

Adobe’s results on Thursday will be important as they will demonstrate whether artificial intelligence tools by companies like OpenAI and Anthropic are disrupting its business.

The other top corporate earnings to watch will be Dollar General, Ulta Beauty, Lennar Corporation, UiPath, and Campbell’s Soup.

S&P 500 Index rising wedge pattern  The other key catalyst for the S&P 500 Index is its technicals, which point to further downside in the near term. 

As the chart above shows, the index has formed a rising wedge pattern, which is made up of two ascending and converging trendlines. It has already moved below the lower side of this pattern and the Strong, Pivot, and Reverse level of the Murrey Math Lines tool.

Therefore, the most likely scenario is where the index continues falling, potentially to the next key support level at $6,000.

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Couloir Capital is pleased to announce that it has updated its research coverage on Roxmore Resources (TSXV: RM) (OTCQX: GARLF) ("Company"). Couloir Capital's mining analyst, Sehaj Anand, MBA, P.Eng.

ToplineGlobal crude oil prices hit their highest level since 2022 early on Monday—pushing gasoline prices at the pump to $3.478 per gallon—as the U.S.-Israel war on Iran showed no signs of abating and President Donald Trump suggested that this was a “small price to pay” in exchange for destroying Iran’s “nuclear threat.”

Fire breaks out at the Shahran oil depot after US and Israeli attacks, leaving numerous fuel tankers and vehicles in the area unusable in Tehran, Iran.

Anadolu via Getty Images

Key FactsEarly on Monday, the global benchmark Brent Crude Futures index soared to $116.71 per barrel, up more than 25% since Friday’s closing price.

The index hit its highest level since 2022, when oil prices spiked following Russia’s invasion of Ukraine.

However, the gains were pared down to $104 a barrel a few hours later after the Financial Times reported that financial ministers of the G7 group of countries will participate in a call to discuss a joint release of oil reserves.

The U.S. benchmark West Texas Intermediate also breached the $115 mark, before also paring back gains to $102.50 per barrel.

GasBuddy’s head of petroleum analysis, Patrick De Haan, warned overnight that there is now a 80% chance of the national average gasoline prices in the U.S. hitting $4 per gallon by next month, “or sooner.”

What Do We Know About The G7 Ministers Call?The Finance Ministers of the G7 countries and International Energy Agency (IEA) Executive Director Fatih Birol will hold a call at 8:30 a.m. E.T. on Monday to discuss a coordinated release of their strategic petroleum reserves, according to FT’s report. If approved the IEA could oversee the release of somewhere between 300-400 million barrels of oil from the multi nation strategic reserves, and potentially help alleviate some of the spike in prices triggered by the war. The report noted that this could help cover nearly one month of total oil demand in the IEA’s 32 member countries.

What Has President Trump Said About Oil Prices?In a post on Truth Social, President Donald Trump appeared to dismiss concerns about soaring oil prices, noting: “Short term oil prices, which will drop rapidly when the destruction of the Iran nuclear threat is over, is a very small price to pay for U.S.A., and World, Safety and Peace.” The president then added: “ONLY FOOLS WOULD THINK DIFFERENTLY!”

How Will This Impact Prices At The Pump?According to AAA’s tracker, the national average gasoline price across the U.S. stood at $3.478 per gallon on Monday, a sharp increase from $2.997 per gallon a week ago. In his analysis, De Haan wrote: “Despite the large jump already seen, gasoline prices are likely to rise further this week…wholesalers and refiners may implement rare ‘intra-day' price increases at fuel terminals starting Monday morning.” De Haan said he expects the national average price to rise from its current $3.45 per gallon to “roughly $3.75–$3.95 this week alone.” If the $4 mark is breached, it would be the first time this has occurred since August 2022.

Chief CriticIn a post on X, Senate Minority Leader Chuck Schumer, D-N.Y., wrote: “Due to Donald Trump’s reckless war of choice, gas prices have surged to their highest levels in years. His response? “If they rise, they rise.” He couldn’t care less. Today, I demanded Trump release oil from the Strategic Petroleum Reserve IMMEDIATELY to bring relief to Americans at the pump.”

How Have U.s. Stock Futures Reacted?U.S. stock futures were down across the board early on Monday amid the rise in oil prices. The benchmark S&P 500 Futures index fell 0.89% to 6,681.25 points, while Dow Futures sank around 1% to 47,031 points. The tech-centric Nasdaq Futures fell to 24,417.25 points, down 1% since Friday’s close.

TangentAs oil prices soared major Asian stock markets were hit hard on Monday. Japan’s benchmark Nikkei 225 index fell more than 5%, while South Korea’s KOSPI sunk 6.2%. India’s Sensex index dropped 2.27% while Hong Kong’s Hang Seng fell 1.61%.

Further ReadingIran War: Hegseth Expects ‘More Casualties’ But Reiterates Trump’s ‘Surrender’ Demand As Tehran Appoints New Leader (Forbes)

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Digital Vision. / Getty Images

MP Materials (NYSE: MP) sits at the center of one of the most consequential supply chain shifts in modern American industrial policy. With shares at $58.23, up 138.65% over the past year, the market is pricing in a geopolitical shift that has drawn significant attention: the U.S. has almost no domestic rare earth supply chain, and MP is the only company capable of building one at scale.

The Only Game in Town MP operates the only integrated rare earth mining and processing platform in the United States, anchored by the Mountain Pass mine in California and the Independence magnetics facility in Fort Worth, Texas. “China accounts for roughly 90% of global NdPr production, yet even there, most of that output comes from just 2 hard rock mines and refineries,” CEO James Litinsky noted on the Q3 2025 earnings call. Outside China, only Mountain Pass and Australia’s Mount Weld operate at meaningful scale. That structural scarcity is MP’s most durable competitive advantage.

Government Backing Changes the Risk Profile In October 2025, MP activated a landmark Price Protection Agreement with the U.S. Department of Defense, guaranteeing a $110 per kilogram floor price for NdPr oxide. The Pentagon holds a 15% stake in the company and has committed to a 10-year offtake agreement supporting the new Texas magnet campus. The financial impact was immediate: Q4 2025 delivered $51.02 million in PPA income, flipping the company to $9.43 million in net income versus a $22.34 million loss in Q4 2024. EPS of $0.09 beat the consensus estimate of $0.02.

The 10X Build-Out MP is breaking ground in 2026 on a 120-acre campus in Northlake, Texas, designed to produce nearly 10,000 metric tons of rare earth magnets annually by 2028, attracting roughly $200 million in state and local incentives. Apple and General Motors are already signed as customers. “We have 100% offtake secured for 10X,” CFO Ryan Corbett confirmed on the Q3 call.

What Gives Investors Pause The bull case carries real risks. Insiders sold approximately $19.2 million worth of shares in the most recent quarter, including CEO Litinsky disposing of 272,600 shares on January 8, 2026. Much of this activity coincided with RSU vesting events, suggesting portfolio rebalancing rather than lost conviction, but the volume warrants attention. Full-year 2025 revenue of $224.44 million slightly missed estimates, and the company remains in heavy investment mode with $172.38 million in capital expenditures last year. Analysts carry an average price target of $78.50, implying meaningful upside, with 15 of 15 analysts rating the stock a Buy or Strong Buy.

The Strategic Inevitability The United States has no viable path to defense and clean energy independence without a domestic rare earth supply chain. MP produced a record 2,599 metric tons of NdPr oxide in 2025, a 101% year-over-year increase. As Litinsky put it: “Self-sufficiency, allied resilience, and national industrial champions are no longer optional. They are the front lines of security.” A China export control announcement is expected on March 25, 2026, a development that could have significant implications for MP given its position as the only domestic integrated rare earth producer.

DENVER, March 09, 2026 (GLOBE NEWSWIRE) -- SHF Holdings, Inc., d/b/a Safe Harbor Financial (“Safe Harbor” or the “Company”) (NASDAQ: SHFS), a leading fintech platform serving the banking, lending, and financial services needs of the regulated cannabis and hemp industries, today released a letter to shareholders from Terrance Mendez, Chief Executive Officer of Safe Harbor.

Dear Fellow Shareholders,

Today, Safe Harbor has a strong financial base and is ready to grow: we are debt-free, hold more than $6 million in cash, and have secured a long-term agreement with a major customer that is expected to generate at least $10.5 million in incremental cash flow. Here is a summary of the past year and why we believe the next chapter is significantly more valuable than the last.

The Numbers Tell the Story

The single most important thing I can tell a shareholder today is this: we eliminated substantially all of the Company's debt in September 2025. Members of management and our Board of Directors participated directly in the financing round that made this possible, because we believe in the long term growth potential of the business we are building. We put our own capital to work alongside yours.

Here is where we stand financially:

More than $6 million cash on hand with no meaningful debt obligations at the end of 2025Long-term revenue visibility through 2031 under our amended agreement with Partner Colorado Credit Union (PCCU) that is expected to increase cash flow by over $10 million over the term29% deposit growth in Emerging U.S. Markets over the 12 months ended February 4, 2026, driven by more than 100 new accounts
In short: the balance sheet that was a liability 12 months ago is now what we believe to be a foundation for growth.

Improved Profitability: More Revenue, Lower Costs, Long Term Stability

On February 9, 2026, we announced a significant improvement to our relationship with PCCU, our primary banking partner and a key shareholder. The new agreement extends our partnership by two years through the end of 2031 and restructures our economics in a way that directly benefits shareholders. We exchanged a future risk protection for an opportunity for immediate and consistent cash revenue, a transaction that is profitable precisely because the cost of bearing that risk is less than the revenue we expect to receive for doing so. Under the modified agreement, our share of loan interest income increases from approximately 35% to 65% nearly doubling our participation in the loan portfolio we work every day to build and service.

The modified agreement is expected to generate an estimated $9 million in incremental revenue and over $1.5 million in total incremental cost savings over the 6.25 year term assuming no growth in deposits. However, as we grow deposits and facilitate new loans under this modified agreement, the benefits should expand. This amended agreement with PCCU helps to enhance the stability and visibility of our revenue model through 2031, removes growth barriers, and generates significant cash revenue and cost savings in exchange for non-cash risk exposure, positioning us well for profitable expansion with our valued long-term strategic partner.

After securing a more stable and profitable relationship with PCCU, we are simultaneously executing a deliberate diversification strategy to broaden our revenue base across bank services, managed services, lending, technology integration, and programs to help financial institutions scale.

Securing a strong and stable foundation with PCCU was priority one. Priority two is executing a deliberate strategy to diversify our revenue across four growth vectors.

Launch of our Fully Managed Cannabis Banking Program

In September we launched our Fully Managed Cannabis Banking Program, offering a compliant turnkey program designed for community banks, credit unions, and financial institutions seeking to serve the legal cannabis market. Safe Harbor manages everything, including compliance, onboarding, account support and loan syndications while deposits remain directly at the financial institution. We are actively engaged with new financial institutions interested in partnering through this program, and it represents one of the most significant near-term revenue opportunities in our pipeline. We believe this strategy strengthens our long-term risk profile and positions Safe Harbor for sustainable, profitable growth.

Expanded Lending Platform

One year ago, Safe Harbor's lending capabilities were largely limited to commercial real estate. Today, Safe Harbor has meaningfully expanded its lending capabilities such that we now have the ability to structure financing across the entire operator lifecycle, from startup funding of as little as $5,000 to transactions as large as $25 million or more, funded through our network of credit unions, regional banks, family offices, and private equity relationships. We closed one of our first startup capital transactions for a first-time dispensary operator in Massachusetts, which is a transaction that would not have been possible under our prior lending framework. We have built the infrastructure to be the financial partner cannabis operators turn to at every stage of their growth, leveraging our domain expertise and disciplined underwriting to identify, evaluate, and price risk appropriately for our financial partners.

Managed Services and Back Office Solutions

We launched our Managed Services platform that delivers end-to-end back-office solutions to cannabis operators spanning treasury management, HR outsourcing, employee banking, accounts receivable management, and cash flow advisory. These services carry higher margins, generate recurring free cash flow, and create depositor stickiness. In December, we acquired the core operating assets and active client contracts of 420 IT Solutions, a recognized cannabis-focused managed services firm, and hired its founders to lead our Managed Services platform. We acquired an established business with proven leadership and strong industry relationships immediately extending our reach.

Critically, we believe these services differentiate Safe Harbor's banking relationships from those offered by competing financial institutions, creating a depth of partnership that a traditional bank simply cannot replicate.

Safe Harbor Advantage Partner Network

We are expanding beyond core banking and lending to offer the operational infrastructure our clients need to run more stable, resilient businesses. In January 2026, we began offering cannabis-specific insurance solutions through partnerships with Frontier Risk and AlphaRoot. Clients can now access property, workers' compensation, general liability, product liability, and related risk management coverage all tailored for cannabis operators. This is the first offering in what we intend to be a broader suite of compliant, curated services that deepen our client relationships and improve retention. That same month, we also expanded our payments solutions portfolio through new partnerships with Lüt and GreenCard. Lüt's closed-loop, wallet-based payment system provides operators with guaranteed funds and uninterrupted payment flow, while GreenCard unifies retail, delivery, e-commerce, and wholesale transactions on a single platform, transforming lengthy check cycles into next-day ACH settlement. Together, these additions give our clients the flexibility, redundancy, and operational resilience they need in an industry where payment infrastructure remains one of the most persistent challenges. These launches are the first offerings in what we intend to be a broader suite of compliant, curated services that deepen our client relationships and improve retention.

The Cannabis Market Is Moving Our Way

Since its founding, Safe Harbor has facilitated more than $26 billion in cannabis-related transactions across 41 states and territories. We have been doing this longer than almost anyone. And for the first time in years, federal policy appears to be moving in our direction.

The Trump Administration's Executive Order to complete Rescheduling in December represents a meaningful policy shift. We believe reclassification, once implemented, would improve the financial position of cannabis operators, reduce business attrition, and increase participation by financial institutions expanding the addressable market for Safe Harbor's services. We are cautiously optimistic and are positioning the business to capitalize on this tailwind when it arrives, not scramble to catch up after the fact.

We are also generating real results in emerging state markets right now. Deposit balances in states with recently launched or expanded cannabis programs including New York, New Jersey, Illinois, Florida, Ohio, and Kentucky grew 29% over the past year and now represent 31% of our total average deposit base. These are the markets where the next wave of cannabis banking demand will originate, and we are already there.

More to Come in 2026

We are a leaner, better-capitalized, and more diversified company than we were 12 months ago and we are building new revenue lines. While we’ve made significant progress, we’re continuing to develop additional compliant solutions and look forward to announcing them when appropriate. We see much more opportunity to create value, and intend to capture it through continued execution.

In closing, our interests are aligned with that of our shareholders. Members of Management and our Board of Directors participated in the financing round that eliminated substantially all of the Company’s outstanding debt and provided growth capital. We did this because we believe the risk/reward profile of the Company is meaningfully better than it was a year ago. With the progress we have made with our amended commercial alliance agreement with PCCU as well as strengthening our capital position, launching new client-focused services, and adding talent with deep cannabis domain expertise, I am proud to say we have made significant strides in turning Safe Harbor’s business around and positioning the Company for future success.

I would like to thank all of our valued shareholders, financial partners and customer base for your continued support.

Regards,
Terrance Mendez
Chief Executive Officer
Safe Harbor Financial

About Safe Harbor:
Safe Harbor is a cannabis-exclusive financial platform delivering smarter banking, lending, payments and business services tailored to how the cannabis industry actually operates. As one of the original pioneers of compliant cannabis banking in the U.S., Safe Harbor has facilitated more than $26 billion in cannabis-related transactions across 41 states and territories. Through its proprietary Cannabis Banking Solutions™ Platform and network of regulated financial institution partners, Safe Harbor empowers cannabis operators to gain clarity, control and confidence in their financial operations. From daily banking to long-term growth, Safe Harbor provides real solutions and personal support built exclusively for cannabis. Safe Harbor is a financial technology company, not a bank. Banking services are provided by our partner financial institutions. For more information, visit www.SHFinancial.org.

Cautionary Statement Regarding Forward-Looking Statements:
Certain information contained in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included herein may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements may include, but are not limited to, statements with respect to the rescheduling of cannabis, the passing of the SAFER Banking Act and any other proposed regulations, the potential positive effects of any rescheduling or legislation, trends in the cannabis industry, including proposed changes in U.S and state laws, rules, regulations and guidance relating to Safe Harbor’s services; Safe Harbor’s growth prospects and Safe Harbor’s market size; Safe Harbor’s projected financial and operational performance, including relative to its competitors and historical performance; success or viability of new product and service offerings Safe Harbor may introduce in the future; the impact volatility in the capital markets, which may adversely affect the price of Safe Harbor’s securities; the outcome of any legal proceedings that have been or may be brought by or against Safe Harbor; Safe Harbor’s relationship with PCCU; and other statements regarding Safe Harbor’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “outlook,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Safe Harbor’s filings with the U.S. Securities and Exchange Commission. Safe Harbor undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Safe Harbor Investor Relations Contact: 
[email protected]

Safe Harbor Media Relations Contact:
[email protected]

The move spares the concerts-and-ticketing giant from the threat of its business being broken up.

UBS has told clients the central question for oil markets is no longer whether prices will rise, but how high they must go before demand is destroyed, as the near-closure of the Strait of Hormuz shows no immediate sign of easing.

Brent crude surged to an intraday high of $109 per barrel earlier in Monday's session before pulling back to $97.06, still up 12% on the day.

The Strait of Hormuz, the narrow waterway through which around 20 million barrels of crude and refined products normally pass each day, is now seeing only two or three tanker crossings daily against the typical 30 to 35.

Iraq, which has almost no domestic storage capacity, has already been forced to shut in a substantial portion of its production, with Kuwait also reported to be curbing output for the same reason.

Saudi Arabia is rerouting crude via the East-West pipeline to its Yanbu terminal on the Red Sea, partially bypassing the Strait, but UBS says whether the UAE can do the same remains unclear following reported damage to the port of Fujairah.

The knock-on effects are already severe in refined products markets, where gasoil futures in Europe and heating oil contracts in the United States have both crossed $150 per barrel, roughly double their levels at the start of the year.

UBS describes strategic reserve releases as a limited tool, calling them a drop in the ocean relative to the scale of the disruption if the closure is prolonged.

The bank's own end-2026 Brent forecasts of $65 to $67 per barrel imply it expects the Strait to eventually reopen and markets to normalise, but at current spot levels of $97.06 that scenario would represent a fall of around 33% from here.

For investors, the note frames the trade as binary: a prolonged closure means prices grind higher until consumption falls sharply, while a rapid resolution would bring prices down quickly but not all the way back to pre-conflict levels, as restarting production and export flows takes time.

Brent crude (BZ=F) was trading at $97.06 at time of publication.

March 09, 2026 07:00 ET  | Source: NRx Pharmaceuticals, Inc.

Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.Now accepting patients, call 1-833-4HOPETMS WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen, combined with physician-led psychotherapy. This clinic location is the most recent addition to HOPE’s growing network of clinics.

Peer-reviewed scientific publications have shown an 87% clinical response rate with a short-term treatment protocol in patients with treatment-resistant depression. With the addition of hyperbaric oxygen therapy, pilot programs have shown a 90% rate of return to full function in patients with depression and post-traumatic stress disorder. TMS has also been shown in some studies to demonstrate improved memory and cognition in some patients with Alzheimer’s disease and Traumatic Brain Injury. HOPE previously announced a nationwide partnership with neurocare AG and expects to bring the latest developments in the non-invasive treatment of these conditions to this flagship location.

“Prior to the advent of modern neuroplastic therapies for depression, PTSD, and related conditions, patients were primarily treated with traditional antidepressants which are now understood to work only 37% of the time and to have a broad array of negative side effects. In severe cases, the only FDA-approved treatment was electroshock therapy. We at HOPE are thrilled to be able to offer state-of-the-art neuroplastic therapy with a potential for rapid return to functional daily life, often without the need for daily medications,” said Dr. Jonathan Javitt, CEO of HOPE Therapeutics. 

The clinical results that have been published in the medical literature are based on a broad array of patients and may or may not reflect the results achieved by any individual patient.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetics stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve rapid remission from treatment resistant depression.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
[email protected]

__________________
1 Ketamine is currently FDA-approved as an anesthetic but is not indicated for use in treating depression, although it is used by practicing physicians for that purpose and is the subject of numerous scientific publications. It has been identified by the US Department of Veterans Affairs as a drug that may be "medically necessary" for "Treatment Resistant Depression" and for "Depression with severe suicidal ideation. The appropriateness of ketamine for any particular patient is a doctor/patient decision that can only be made within the scope of clinical practice of medicine.

March 09, 2026 07:00 ET  | Source: Relmada Therapeutics

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse events and no treatment-related discontinuations Data reinforces advancement of NDV-01 into Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC).

The Phase 2 trial of NDV-01 demonstrated a 12-month complete response (CR) rate of 76% with a favorable safety profile. Notably, a 12-month CR rate of 80% was achieved in the BCG-unresponsive population, one of the most difficult-to-treat segments of NMIBC. Taken together, these findings support the potential best-in-class profile of NDV-01 and support advancement into the Phase 3 RESCUE registrational program evaluating NDV-01 in both 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC.

“These 12-month data show the potential durability of NDV-01’s clinical response profile while continuing to demonstrate a clean safety profile,” said Raj S. Pruthi, MD, Chief Medical Officer-Oncology of Relmada Therapeutics. “Importantly, we continue to observe strong responses in patients with BCG-unresponsive disease, with no progression to muscle-invasive disease and no patients requiring radical cystectomy. We believe these interim results provide meaningful clinical validation of the program and support advancing NDV-01 into the registrational Phase 3 RESCUE program with two separate registrational pathways: 2L BCG-unresponsive and adjuvant intermediate-risk, which we expect to initiate in mid-2026.”

“I am highly encouraged by NDV-01’s high response rates, 12-month durability and favorable tolerability profile. Building on the clinical community’s familiarity with conventional Gem/Doce, these Phase 2 results provide robust validation of NDV-01’s novel sustained release formulation. In addition, NDV-01’s less than 5-minute administration simplifies dosing for clinical staff, supporting broad adoption in community urology practices where ~80% of NMIBC patients are treated – and potentially offering a significantly more streamlined user experience than currently approved therapies,” said Max Kates, MD, Director of Urologic Oncology at Johns Hopkins and Relmada Clinical Advisor.

Highlights of the 12-month follow-up data from the Ongoing Phase 2 study of NDV-01:

Clinical Results (Response Data)Complete Response Anytime95% (36/38)3 month87% (33/38)6 month86% (25/29)9 month85% (22/26)12 month76% (19/25)12-month KM analysis83%N=48 patients dosed in overall population; KM: Kaplan-Meier analysis
Efficacy in BCG-Unresponsive Subpopulation**:

Clinical Results (Response Data)Complete Response Anytime94% (16/17)3 month82% (14/17)6 month86% (12/14)9 month91% (10/11)12 month80% (8/10)12-month KM analysis84%N=20 patients dosed in BCG-UR subpopulation; ** BCG-UR defined by FDA definition; BCG-UR: Bacillus Calmette-Guérin (BCG) – Unresponsive; KM: Kaplan-Meier analysis No patient had progression to muscle-invasive diseaseNo patient underwent a radical cystectomyNo patients had a ≥ Grade 3 treatment related adverse event (TRAE)No patients discontinued treatment due to AEsOf the 48 patients who received ≥ 1 dose, 30 (63%) experienced a treatment-related adverse event (AE).Among treatment-related AEs, 54% were transient uncomfortable urination (dysuria, <24 hours, Grade 1)8% had an asymptomatic positive urine culture8% had hematuria
Phase 3 RESCUE Registrational Pathways:

Registrational Pathway 1 – An open label randomized controlled trial in intermediate-risk NMIBC of adjuvant therapy following TURBT (NDV-01 vs. observation). There are no approved treatments for adjuvant intermediate risk NMIBC, which we estimate affects ~75,000 patients/year in the US.

Primary endpoint: Disease Free Survival (DFS)Key secondary endpoints: High-grade recurrence free survival (HG-RFS), progression free survival (PFS), quality of life (QOL) metrics Registration Pathway 2 – A single-arm trial in second line (2L) BCG-unresponsive NMIBC with carcinoma in situ (CIS) patients who are currently refractory to approved or developmental therapies. Patients with BCG-unresponsive NMIBC with CIS who fail first line (1L) therapies, which we estimate to affect ~5,000 patients/year in the US, have few, if any, effective treatment alternatives to radical cystectomy.

Primary endpoint: Complete response (CR) rate at any timeKey secondary endpoint: Duration of response (DOR), progression free survival (PFS), recurrence free survival (RFS) amongst responders Expected Upcoming NDV-01 Milestones:

NDV-01 United States IND clearance – Mid-2026Phase 3 RESCUE Program Initiation – Mid-2026Initial 3-month results from Phase 3 2L BCG-unresponsive study expected by YE 2026
About NDV-01

NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce), in development for the treatment of non-muscle invasive bladder cancer. It is designed to enable Gem/Doce bladder retention and gradual drug release over 10 days. The formulation creates a soft matrix that enhances local exposure while minimizing systemic toxicity. The NDV-01 formulation is ready to use, convenient to administer in-office in approximately 5 minutes and does not require anesthesia or specialized equipment. It is protected by patents through 2038.

About the Phase 2 Study

The Phase 2 study (NCT06663137) is an open-label, single-arm, single-center study evaluating the safety and efficacy of NDV-01 in patients with HG-NMIBC. Patients are treated with NDV-01 in a biweekly induction phase, followed by monthly maintenance for up to one year, with regular assessments via cystoscopy, cytology, and biopsy, as indicated. The primary efficacy endpoints are safety and complete response rate (CRR) at 12 months, and secondary efficacy endpoints are duration of response (DOR) and event free survival (EFS).

About NMIBC

NMIBC represents 75-80% of all bladder cancer cases and is associated with high recurrence (50 – 80% over 5 years). With over 744,000 prevalent cases in the U.S. and limited treatment options, the market opportunity is significant. High-grade BCG-unresponsive disease represents one of the most difficult-to-treat NMIBC subtypes, with limited bladder-sparing options. Intermediate-risk NMIBC in the adjuvant setting has no currently approved therapies. NDV-01 has the potential to serve as a frontline or salvage therapy and could be applicable across multiple NMIBC subtypes.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Forward-Looking Statements:

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada’s product candidates to progress, including the potential for Phase 2 NDV-01 data to continue to deliver positive results supporting further development, potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, or that future NDV-01 and/or sepranolone clinical results will be acceptable to the FDA, failure to secure adequate NDV-01 and/or sepranolone drug supply, the Company’s cash runway and sufficiency of the Company’s cash resources and uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete list.

Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]

Media Inquiries:
Corporate Communications
[email protected]

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). The Company also announced that it will host a virtual key opinion leader (KOL) event on Tuesday.

TORONTO, March 9, 2026 /PRNewswire/ - Denarius Metals Corp. (Cboe CA: DMET) (OTCQX: DNRSF) ("Denarius Metals" or the "Company") announced today an update on its capital structure in light of the exercises of warrants that have been taking place since the beginning of 2026. To date, the Company has received total gross proceeds of approximately CA$16.7 million in cash from the exercise of approximately 27.7 million warrants at exercise prices ranging from CA$0.60 to CA$0.66 per share.

Surging oil prices are upending the stock market. But so far, one sector seems to be getting hit harder than others—the travel industry.

HomeDividends AnalysisDividend Quick Picks

SummaryTwo elite income machines just fell to valuations investors rarely get to see.These stocks have traded down sharply due to scary-sounding headlines, but the data tells a very different story.The yields are already massive, and the upside could surprise many investors.Looking for a portfolio of ideas like this one? Members of High Yield Investor get exclusive access to our subscriber-only portfolios. Learn More » z1b/iStock via Getty Images

One of the best times to invest in a stock is when it is a high-quality business with an impressive track record, a skilled management team, high-quality assets, and a business model, and yet trades at a clear discount

48.84K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

March 09, 2026 07:05 ET  | Source: Bitfarms Ltd.

TORONTO and NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American digital infrastructure and energy company, today announced a series of strategic hires across its infrastructure and corporate teams. These additions bring deep expertise in power development, large‑scale construction, permitting, and corporate scaling as Bitfarms accelerates build‑outs across its portfolio.

“We are excited to welcome Tara, Michael, Christopher, Paul, Kevin, and Tom to our leadership team,” said CEO Ben Gagnon. “As we continue toward U.S. domiciliation and advance our sites, building a seasoned domestic leadership bench is essential. Our recent hires bring substantial industry experience, with an average of more than 20 years in digital and power infrastructure and extensive backgrounds in complex construction and specialized HPC data center development. Our new leaders will be based out of our New York office, positioning us to operate with greater coordination and focus as we enter the next phase of our growth.”

Infrastructure Leadership Strengthened to Advance HPC/AI Development

Michael Byrne joins as Senior Vice President of Construction. Michael brings a decade of hyperscale data center project delivery experience across North America, South America and Europe. Michael’s career includes leadership roles at Linesight and Aurecon where he oversaw significant hyperscale development programs, leading program management, multi‑region execution, commercial governance, contractor oversight, and lifecycle delivery from concept through commissioning. At Bitfarms, he will lead end‑to‑end construction execution for our HPC/AI data center development portfolio, applying his proven ability to manage megaproject portfolios.

Christopher Ruppel joins as Senior Vice President of Power. Chris brings more than two decades of experience bridging advanced compute infrastructure with energy systems optimization. Chris has led development strategies spanning onsite power, grid‑connected assets, and gas‑to‑power solutions for high‑density AI and edge‑compute environments. His track record includes originating and developing 4 GW of energy projects globally, structuring billions of dollars in project financings, and advising data center operators on resilient, commercially optimized energy strategies. Chris joins Bitfarms from MARA Holdings, where he served as Head of Energy Development. At MARA, he led the strategy for the Digital Energy division, focusing on behind-the-meter power, thermal strategies, and demand-response initiatives.

Paul Peterson joins Bitfarms as Vice President of HPC Operations. Paul brings nearly two decades of deep expertise in data centers, critical environments, and engineering services and operations. His career includes senior leadership roles at JLL Global and CBRE, where he oversaw large‑scale engineering projects, guided complex infrastructure strategies, advanced global assessment and compliance programs, and drove operational excellence for enterprise, colocation, and hyperscale clients. With a foundation that spans hands‑on engineering, facility management, auditing, and strategic technical leadership, Paul has repeatedly served as a trusted advisor to stakeholders—translating technical risk into business impact, strengthening reliability programs, and shaping industry‑leading standards.

Kevin Roberts joins Bitfarms as Director of Permitting. Kevin has over two decades of experience as a senior project development, environmental and regulatory leader across energy infrastructure, utilities, and hyperscale data centers. He has directed multi-million development portfolios and led permitting and compliance for over 50 natural gas facilities, more than 1,000 miles of pipeline, and multiple utility‑scale data center developments across the United States. In his role at Bitfarms, he will utilize his expertise in environmental compliance, site selection, utilities coordination, and multidisciplinary project management to ensure Bitfarms’ HPC/AI campuses progress efficiently through federal, state, and local approval processes.

Key Additions to Corporate Leadership

Tara Goldstein has been appointed Senior Vice President of Marketing. Tara is responsible for building and leading Bitfarms’ global marketing and communications function, overseeing brand strategy, corporate narrative, digital presence, and enterprise-wide positioning. Tara has over two decades of experience leading strategy, storytelling, and placemaking for high-profile real estate and technology-driven companies. Before leading a full-service creative agency, she served as Senior Vice President of Marketing at Brookfield Properties, overseeing marketing for their 98-million-square-foot global office, retail, and residential portfolio. During her tenure, she led the rebrand and repositioning of Brookfield Place New York, the multi-phased Manhattan West development, and numerous other award-winning initiatives.

Thomas Tyree III has been appointed Senior Vice President, Finance & Strategy at Bitfarms. Tom leads financial and strategic initiatives supporting Bitfarms’ HPC/AI transition, including capital markets activities, capital allocation, and strategic partnerships. He brings extensive experience in corporate finance, financial analysis, and execution of complex transactions across energy, power, and infrastructure. Prior to Bitfarms, Tom was a member of the executive leadership team at Stronghold Digital Mining, where he led the company’s initial public offering, several structured financings, and the strategic review process that led to Stronghold’s sale to Bitfarms. Before Stronghold, Tom worked at Riverstone Holdings, a $40 billion asset-management firm focused on energy, power, and infrastructure investments.

About Bitfarms Ltd.

Bitfarms is a North American digital infrastructure and energy company that develops, owns, and operates data centers and energy infrastructure for high-performance computing and next-generation-technology applications, including artificial intelligence.

Bitfarms’ 2.1 GW North American energy portfolio is comprised of energized, under development, and pipeline MW, located in established data center clusters, with robust access to power and fiber infrastructure.

Bitfarms is headquartered in New York, NY and Toronto, ON and traded on the Nasdaq and the Toronto Stock Exchange.

To learn more about Bitfarms’ events, developments, and online communities:
www.bitfarms.com
http://x.com/Bitfarms_io
https://www.linkedin.com/company/bitfarms/

Forward-Looking Statements  
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. The statements and information in this release regarding the strategic hires to support HPC/AI infrastructure development and the anticipated contributions of new leadership and other statements regarding future growth, plans and objectives of Bitfarms are forward-looking information.

Any statements that involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “prospects”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. This forward-looking information is based on assumptions and estimates of management of Bitfarms at the time they were made, and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Bitfarms to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors, risks and uncertainties include, among others: the anticipated benefits of the U.S. redomiciliation, and the anticipated rebalancing of operations to North America and from Bitcoin mining to digital infrastructure may occur on a timeline different than the expectations of Bitfarms, may not occur at all, and may have unanticipated costs for Bitfarms; the anticipated benefits of the rebalancing of operations to North America and the North American energy and compute infrastructure strategy may not be realized or the realization of such benefits may be delayed; an inability to apply Bitfarms’ data centers to HPC/AI opportunities on a profitable basis; a failure to secure long-term contracts associated with HPC/AI customers on terms which are economic or at all; the construction and operation of new facilities may not occur as currently planned, or at all; expansion of existing facilities may not materialize as currently anticipated, or at all; the construction and operation of new facilities may not occur as currently planned, or at all; expansion of existing facilities may not materialize as currently anticipated, or at all; failure of the equipment upgrades to be installed and operated as planned; the availability of additional power may not occur as currently planned, or at all; expansion may not materialize as currently anticipated, or at all; the power purchase agreements and economics thereof may not be as advantageous as expected the risks of an increase in electricity costs, cost of natural gas, changes in currency exchange rates, energy curtailment or regulatory changes in the energy regimes in the jurisdictions in which Bitfarms operates and the potential adverse impact on profitability; future capital needs and the ability to complete current and future financings, as well as capital market conditions in general; share dilution resulting from equity issuances; and the adoption or expansion of any regulation or law that will prevent Bitfarms from operating its business, or make it more costly to do so. For further information concerning these and other risks and uncertainties, refer to Bitfarms’ filings on www.sedarplus.ca (which are also available on the website of the U.S. Securities and Exchange Commission at www.sec.gov), including Bitfarms’ annual information form for the year ended December 31, 2024, management’s discussion & analysis for the year-ended December 31, 2024 and the management’s discussion and analysis for the three and nine months ended September 30, 2025. Although Bitfarms has attempted to identify important factors that could cause actual results to differ materially from those expressed in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended, including factors that are currently unknown to or deemed immaterial by Bitfarms. There can be no assurance that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on any forward-looking information. Bitfarms does not undertake any obligation to revise or update any forward-looking information other than as required by law. Trading in the securities of Bitfarms should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the Toronto Stock Exchange, Nasdaq, or any other securities exchange or regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A 

Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H’28

Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H’26

Phase 1 healthy volunteer data for DNTH212 anticipated in 2H’26; update on indication prioritization planned for 1H’26

$514.4 million of cash as of December 31, 2025 provides runway into 2028

Investor conference call and webcast to be held to discuss the CAPTIVATE trial interim responder analysis today, March 9, 2026 at 8:00 a.m. ET 

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2025, announced a GO decision in the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and provided an update on other recent business achievements.

“It is truly exciting to be part of a company developing potential best-in-disease therapies for patients suffering from severe autoimmune diseases. I am very proud of the impressive level of execution the Dianthus team continues to deliver against our ambitious goals,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “With claseprubart, we are building a leading neuromuscular franchise with a target product profile that aims to combine best-in-class efficacy and safety with the convenience of an infrequent, subcutaneous, self-administered autoinjector that has the potential to meaningfully shift the treatment paradigm and standard of care for more than 150,000 patients in the U.S. living with gMG, CIDP and MMN.”

Claseprubart (DNTH103) Clinical Development

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.

Generalized Myasthenia Gravis (gMG)

Phase 3 trial expected to initiate mid-2026, with top-line results expected in 2H’28: Following the successful completion of our end-of-Phase 2 meeting with the FDA in the first quarter of 2026, a Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients is expected to initiate in mid-2026, with top-line results expected in 2H’28.
Claseprubart data presented at Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, March 8-11, 2026: Three poster presentations describing claseprubart Phase 2 MaGic results and in vitro data are available on the Investors section of the Dianthus website under Scientific Publications. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Early GO decision announced in Phase 3 CAPTIVATE trial: The target for the Part A interim responder analysis was a response rate of 50% or greater (i.e., ≥20 confirmed responders out of first 40 participants to complete Part A) based on precedent set with aC1s inhibition. This GO decision was reached early, after 20 confirmed responders were achieved with less than 40 planned participants completing open-label Part A of the trial. Dianthus expects to provide CAPTIVATE Part B top-line guidance by YE’26. Multifocal Motor Neuropathy (MMN)

Phase 2 MoMeNtum MMN trial remains on track for top-line results in 2H’26: The MoMeNtum trial is an ongoing global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with MMN. DNTH212 Clinical Development

DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes.

Phase 1 data anticipated in 2H’26: A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) was initiated in December 2025, with top-line results in healthy volunteers expected in 2H’26. An update on indication prioritization for DNTH212 is planned for 1H’26. Full Year 2025 Financial Results

Cash Position – $514.4 million of cash, cash equivalents and investments as of December 31, 2025 is projected to provide runway into 2028. R&D Expenses – Research and development (R&D) expenses for the year ended December 31, 2025 were $145.6 million, inclusive of $10.1 million of stock-based compensation, compared to $83.1 million for the year ended December 31, 2024, which included $5.6 million of stock-based compensation. This increase in R&D expenses was primarily driven by higher clinical costs, upfront and clinical development milestones for DNTH212, and increased headcount to support claseprubart Phase 2 and Phase 3 development.G&A Expenses – General and administrative (G&A) expenses for the year ended December 31, 2025 totaled $34.3 million, inclusive of stock-based compensation of $12.7 million, compared to $25.0 million for the year ended December 31, 2024, which included $7.3 million of stock-based compensation. This increase in G&A expenses was primarily due to increased headcount.Net Loss – Net loss for the year ended December 31, 2025 was $162.3 million or $4.20 per share (basic and diluted) compared to $85.0 million or $2.55 per share (basic and diluted) for the year ended December 31, 2024.Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2025, please refer to the Form 10-K filed with the SEC. CAPTIVATE Investor Conference Call & Webcast to be Held at 8:00 a.m. ET Today
Dianthus Therapeutics will host an investor call and webcast to discuss the CAPTIVATE interim responder analysis today, March 9, 2026 at 8:00 a.m. ET. To access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN. 

The live webcast may be accessed via the Investors section of the Dianthus Therapeutics website at https://investor.dianthustx.com/. A replay of the webcast will be available following the call. The presentation that will be used on this webcast is available here.

About Claseprubart (DNTH103)
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Dianthus is building a neuromuscular franchise with claseprubart and expects to initiate a Phase 3 trial in generalized Myasthenia Gravis in mid-2026, with top-line results expected in 2H’28, report top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in 2H’26, and provide an update on timing of top-line data from Part B of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy by YE’26.

Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.

About DNTH212
DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) is ongoing, with top-line results in healthy volunteers expected in 2H’26.

DNTH212 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart and DNTH212, and any developments or results in connection therewith, including the target product profile and administration of claseprubart and DNTH212; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the clinical trial designs or indications; expectations regarding the time period over which the Company’s capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding market size, patient population size, and potential opportunities for complement therapies, in particular with respect to claseprubart and DNTH212. Claseprubart and DNTH212 are investigational agents that are not approved as therapies in any indication in any jurisdiction worldwide. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the preliminary interim analysis based on a limited number of patients from the Part A open label portion of the claseprubart CAPTIVATE study in patients with CIDP may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study, that the development of claseprubart or DNTH212 may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
[email protected]

 DIANTHUS THERAPEUTICS, INC.
Consolidated Balance Sheets
(unaudited, in thousands)      December 31,   2025  2024 Assets      Current assets:      Cash and cash equivalents $51,087  $22,792 Short-term investments  353,208   252,449 Receivable from former related party  —   807 Accounts receivable, net  52   — Prepaid expenses and other current assets  5,091   4,856 Total current assets  409,438   280,904 Long-term investments  110,135   81,728 Property and equipment, net  296   194 Right-of-use operating lease assets  1,337   1,553 Other assets and restricted cash  9,716   9,629 Total assets $530,922  $374,008 Liabilities and Stockholders’ Equity      Current liabilities:      Accounts payable $9,725  $4,579 Accrued expenses  19,452   13,074 Current portion of deferred revenue  1,188   479 Current portion of operating lease liabilities  367   320 Total current liabilities  30,732   18,452 Deferred revenue  5,770   1,908 Long-term operating lease liabilities  1,019   1,171 Total liabilities  37,521   21,531 Commitments and contingencies      Stockholders’ equity:      Preferred stock  —   — Common stock  43   31 Additional paid-in capital  829,598   526,732 Accumulated deficit  (336,729)  (174,392)Accumulated other comprehensive income  489   106 Total stockholders’ equity  493,401   352,477 Total liabilities and stockholders’ equity $530,922  $374,008           Dianthus Therapeutics, Inc.Consolidated Statements of Operations and Comprehensive Loss(unaudited, in thousands, except share and per share data)
         Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024Revenues:       License revenue – related party$    —  $999  $      —  $5,909 License revenue 284   326   2,036   326 Total revenues 284   1,325   2,036   6,235         Operating expenses:       Research and development 59,895   26,413   145,638   83,105 General and administrative 9,930   6,828   34,331   24,994 Total operating expenses 69,825   33,241   179,969   108,099         Loss from operations (69,541)  (31,916)  (177,933)  (101,864)        Other income/(expense):       Interest and investment income 5,267   3,991   16,119   17,365 Gain/(loss) on investment in related party 254   (160)  508   148 Gain/(loss) on currency exchange, net (3)  27   (57)  (64)Other expense (409)  (380)  (974)  (554)Total other income 5,109   3,478   15,596   16,895         Net loss$(64,432) $(28,438) $(162,337) $(84,969)        Net loss per share attributable to common stockholders, basic and diluted$(1.43) $(0.81) $   (4.20) $(2.55)        Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted             
44,971,383               
35,033,773   38,617,580   33,313,849         Comprehensive loss:       Net Loss$(64,432) $(28,438) $   (162,337) $(84,969)Other comprehensive income/(loss):       Unrealized gain/(loss) on marketable securities 326   (575)  383   59 Total other comprehensive income/(loss) 326   (575)  383   59 Total comprehensive loss$(64,106) $(29,013) $   (161,954) $(84,910)                

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Nektar Therapeutics (NASDAQ: NKTR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Nektar Therapeutics (NASDAQ: NKTR) shares prior to February 26, 2025, you are encouraged to visit https://grabarlaw.com/the-latest/category/current-investigations/, contact Joshua Grabar at [email protected], or call us at 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Nektar securities between February 26, 2025, and December 15, 2025, you can participate in the class action. Please contact Joshua Grabar at [email protected], or call us at 267-507-6085 to learn more.

WHY? According to a recently filed federal securities fraud class action lawsuit, Nektar Therapeutics (NASDAQ: NKTR), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On December 16, 2025, Nektar issued a press release "announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator." The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate.

WHAT CAN YOU DO NOW? If you purchased Nektar Therapeutics (NASDAQ: NKTR) shares prior to February 26, 2025, and still hold shares today, please visit https://grabarlaw.com/the-latest/category/current-investigations/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Nektar securities between February 26, 2025, and December 15, 2025, you can participate in the class action.

#NKTR $NKTR #Nektar

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287739

Source: Grabar Law Office

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us